Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shalby Limited (SHALBY.NS)
Ahmedabad, GJ, IN
Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.27% | -0.29% | +3.82% | +9.80% | -18.63% | -16.64% | -14.77% | +24.31% | -1.19% | -29.05% | -29.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+5.0% Q1'26: +8.5% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+456.9% ★ Q1'26: +267.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-7.9% Q1'26: -23.4% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+6.4% Q1'26: +3.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+2.9% Q1'26: +2.9% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+7.9% Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×4.15× Q1'26: 5.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.83B
est: 3.82B (+0.2%)
|
4.61B
est: 4.69B (-1.7%)
|
4.87B
est: 5.02B (-3.1%)
|
4.31B
est: 4.08B (+5.6%)
|
6.99B
est: 1.23B (+468.7%)
|
8.05B
est: 8.08B (-0.4%)
|
9.34B
est: 9.27B (+0.7%)
|
10.87B
est: 11.04B (-1.6%)
|
11.29B
11.29B – 11.29B
+2.2% YoY
|
11.94B
11.94B – 11.94B
+5.8% YoY
|
28.43B
28.43B – 28.43B
+138.1% YoY
|
11.90B
11.90B – 11.90B
-58.2% YoY
|
12.17B
12.17B – 12.17B
+2.3% YoY
|
| EBITDA |
888.63M
est: 730.60M (+21.6%)
|
927.37M
est: 896.05M (+3.5%)
|
1.00B
est: 913.87M (+9.6%)
|
947.61M
est: 653.53M (+45.0%)
|
1.30B
est: 931.03M (+39.1%)
|
1.61B
est: 1.02B (+56.9%)
|
1.90B
est: 1.77B (+7.0%)
|
1.60B
est: 2.11B (-24.1%)
|
2.16B
2.16B – 2.16B
+2.2% YoY
|
2.28B
2.28B – 2.28B
+5.8% YoY
|
5.43B
5.43B – 5.43B
+138.1% YoY
|
2.27B
2.27B – 2.27B
-58.2% YoY
|
2.32B
2.32B – 2.32B
+2.3% YoY
|
| EBIT |
651.22M
est: 483.63M (+34.7%)
|
574.38M
est: 593.15M (-3.2%)
|
619.46M
est: 527.70M (+17.4%)
|
579.66M
est: 351.47M (+64.9%)
|
787.61M
est: 500.72M (+57.3%)
|
1.13B
est: 550.76M (+104.5%)
|
1.37B
est: 1.17B (+17.1%)
|
944.42M
est: 1.40B (-32.4%)
|
1.43B
1.43B – 1.43B
+2.2% YoY
|
1.51B
1.51B – 1.51B
+5.8% YoY
|
3.60B
3.60B – 3.60B
+138.1% YoY
|
1.50B
1.50B – 1.50B
-58.2% YoY
|
1.54B
1.54B – 1.54B
+2.3% YoY
|
| Net Income |
429.23M
est: 429.07M (+0.0%)
|
316.61M
est: 396.89M (-20.2%)
|
275.87M
est: 344.47M (-19.9%)
|
423.96M
est: 208.69M (+103.1%)
|
541.25M
est: 297.31M (+82.1%)
|
677.01M
est: 327.02M (+107.0%)
|
840.77M
est: 884.95M (-5.0%)
|
62.22M
est: 150.17M (-58.6%)
|
193.08M
193.08M – 193.08M
+28.6% YoY
|
429.07M
429.07M – 429.07M
+122.2% YoY
|
1.39B
1.39B – 1.39B
+225.0% YoY
|
1.61B
1.61B – 1.61B
+15.4% YoY
|
1.84B
1.84B – 1.84B
+14.7% YoY
|
| SGA |
103.24M
est: 167.61M (-38.4%)
|
91.80M
est: 205.57M (-55.3%)
|
105.06M
est: 2.40B (-95.6%)
|
57.54M
est: 1.76B (-96.7%)
|
154.17M
est: 53.87M (+186.2%)
|
251.88M
est: 2.76B (-90.9%)
|
265.60M
est: 406.35M (-34.6%)
|
1.35B
est: 483.95M (+178.5%)
|
494.65M
494.65M – 494.65M
+2.2% YoY
|
523.40M
523.40M – 523.40M
+5.8% YoY
|
1.25B
1.25B – 1.25B
+138.1% YoY
|
521.47M
521.47M – 521.47M
-58.2% YoY
|
533.38M
533.38M – 533.38M
+2.3% YoY
|
| EPS |
4.55
est: 4.00 (+13.8%)
|
2.93
est: 3.70 (-20.8%)
|
2.55
est: 4.90 (-48.0%)
|
3.93
est: 4.45 (-11.7%)
|
5.01
est: 5.55 (-9.7%)
|
6.30
est: 6.30 (+0.0%)
|
7.83
est: 8.25 (-5.1%)
|
0.58
est: 1.40 (-58.6%)
|
1.80
1.80 – 1.80
+28.6% YoY
|
4.00
4.00 – 4.00
+122.2% YoY
|
13.00
13.00 – 13.00
+225.0% YoY
|
15.00
15.00 – 15.00
+15.4% YoY
|
17.20
17.20 – 17.20
+14.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nishita Shukla | Chief Operating Officer | 11M | — |
| Amit Kumar | Chief Financial Officer | 7M | male |
| Tushar Dineshchandra Shah | Associate Vice President, Company Secretary & Compliance Officer | 4M | male |
| Deepak Ananthakrishnan | Global Chief Business Officer | — | male |
| Jigar Todi | Investors Relation & Corporate Strategist | — | — |
| Vikram I. Shah | Founder, Chairman & MD | — | — |
| Babu Thomas | Chief Human Resources Officer | — | male |
| Daniel Hayes | Chief Executive Officer of the US Implant Business | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHALBY.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
